Northern Trust’s GT Biopharma GTBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-3,018
Closed -$37K – 4461
2026
Q2
$37K Buy
+3,018
New +$30.6K ﹤0.01% 4312
2024
Q1
– Sell
-43
Closed -$8.25K – 4447
2023
Q4
$8.25K Hold
43
– – ﹤0.01% 4430
2023
Q3
$7.8K Hold
43
– – ﹤0.01% 4413
2023
Q2
$10.1K Hold
43
– – ﹤0.01% 4477
2023
Q1
$17.8K Sell
43
-1
-2% -$573 ﹤0.01% 4469
2022
Q4
$29.2K Hold
44
– – ﹤0.01% 4402
2022
Q3
$58K Sell
44
-8
-15% -$15.3K ﹤0.01% 4286
2022
Q2
$118K Sell
52
-166
-76% -$315K ﹤0.01% 4104
2022
Q1
$472K Sell
218
-9
-4% -$19.8K ﹤0.01% 3762
2021
Q4
$520K Buy
227
+4
+2% +$15K ﹤0.01% 3793
2021
Q3
$1.13M Sell
223
-78
-26% -$587K ﹤0.01% 3513
2021
Q2
$3.5M Buy
301
+255
+554% +$2.65M ﹤0.01% 3052
2021
Q1
$235K Buy
+46
New +$201K ﹤0.01% 4056

Other funds holding GTBP

Northern Trust's GTBP Position: Q3 2026 in Review

Northern Trust sold out of GT Biopharma (GTBP) in Q3 2026, closing a stake of 3,018 shares — an estimated $37K sold.

Northern Trust first reported a position in GTBP in Q1 2021 and held it in 13 quarters. The position peaked at $3.5M in Q2 2021. 26 funds tracked by Wall St. Rank hold GTBP as of Q3 2026.

  • Northern Trust reported no remaining GT Biopharma position as of Q3 2026 after selling out during the quarter.
  • Northern Trust sold 3,018 GT Biopharma shares in Q3 2026, an estimated $37K.
  • Northern Trust first reported a position in GT Biopharma in Q1 2021 and held it in 13 quarters.
  • Northern Trust's GT Biopharma position peaked at $3.5M in Q2 2021.
  • 26 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2026.

Based on Northern Trust's 13F filing for Q3 2026, filed 16 Nov 2026.